The Salford Lung Study protocol: A pragmatic, randomised phase III real-world effectiveness trial in asthma

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Woodcock, Ashley ^a   Bakerly, Nawar Diar ^b   New, John P ^b   Gibson, J Martin ^b   Wu, Wei ^c   Vestbo, Jørgen ^a   Leather, David ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Asthma; Electronic medical record; Fluticasone furoate vilanterol; Inhaled corticosteroid long acting 2 agonist; Pragmatic randomised controlled trial; Real world evidence

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; FLUTICASONE FUROATE; GLUCOCORTICOID; VILANTEROL;

ADULT; ARTICLE; ASTHMA; CLINICAL PROTOCOL; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PNEUMONIA; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GREAT BRITAIN; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADMINISTRATION, INHALATION; ADULT; ANDROSTADIENES; ASTHMA; BENZYL ALCOHOLS; CHLOROBENZENES; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; MIDDLE AGED;

EID: 84952874268     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0150-8     Document Type: Article

References (9)

1. Busse WW, O'Byrne PM, Bleecker ER, Lotvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52weeks in patients>=12years old with asthma: a randomised trial. Thorax. 2013;68:513-20.
2. New JP, Bakerly ND, Leather D, Woodcock A: Obtaining real-world evidence: the Salford Lung Study. Thorax 2014;69:1152-4.
3. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;2013(158):200-7.
4. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346, e7586.
5. Northwest EHealth: Website. [ www.nweh.org.uk ].
6. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005;99:11-9.
7. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62:219-23.
8. Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep. 2011;11:526-38.
9. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59-99.